Royalty Pharma plc (RPRX) Ownership
RPRX ownership summary
as of October 18, 2026- Institutions
- 87.7% of shares outstanding
- Insiders
- 6.49% of shares outstanding
- Shares outstanding
- 445.3M
- Float
- 417.6M shares available to trade
- Short interest
- 2.93% 12.9M shares short
- Days to cover
- 3.89 short interest up 10.6% vs prior month
- Institutions 87.66%
- Insiders 6.49%
- Other investors 5.85%
RPRX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Morgan Stanley - Brokerage Accounts | 9.64% | 42.9M | $2.62B | −640,036 (−1.5%) | June 30, 2026 |
| 2 | Capital Research & Mgmt Co - Division 3 | 7.92% | 35.3M | $2.15B | +268,034 (+0.8%) | June 30, 2026 |
| 3 | BlackRock Inc | 6.25% | 27.8M | $1.70B | +1.9M (+7.4%) | June 30, 2026 |
| 4 | FMR Inc | 5.51% | 24.5M | $1.49B | −638,428 (−2.5%) | June 30, 2026 |
| 5 | State Street Corp | 2.77% | 12.3M | $752.1M | +1.3M (+12.3%) | June 30, 2026 |
| 6 | T. Rowe Price Associates, Inc. | 2.51% | 11.2M | $682.4M | +9.3M (+478.7%) | June 30, 2026 |
| 7 | Swedbank AB | 2.41% | 10.7M | $653.9M | −860,085 (−7.4%) | June 30, 2026 |
| 8 | Baillie Gifford & Co Limited. | 2.25% | 10.0M | $610.5M | −6.1M (−38.0%) | June 30, 2026 |
| 9 | Capital World Investors | 2.14% | 9.5M | $580.2M | +1.5M (+18.4%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 1.81% | 8.1M | $491.2M | +188,416 (+2.4%) | June 30, 2026 |
| 11 | Caledonia (Private) Investments Pty Ltd | 1.30% | 5.8M | $352.1M | −1.4M (−19.4%) | June 30, 2026 |
| 12 | NORGES BANK | 1.20% | 5.3M | $325.3M | +1.9M (+56.3%) | June 30, 2026 |
| 13 | Vanguard Capital Management, LLC | 1.08% | 4.8M | $294.2M | +294,731 (+6.5%) | June 30, 2026 |
| 14 | Northern Trust Corp | 1.06% | 4.7M | $287.7M | +910,124 (+23.9%) | June 30, 2026 |
| 15 | Royal London Asset Management Ltd | 0.97% | 4.3M | $263.3M | +511,242 (+13.4%) | June 30, 2026 |
| 16 | AQR Capital Management LLC | 0.97% | 4.3M | $262.5M | +523,374 (+13.8%) | June 30, 2026 |
| 17 | Amvescap Plc. | 0.95% | 4.2M | $258.0M | +480,178 (+12.8%) | June 30, 2026 |
| 18 | Bank of America Corp | 0.93% | 4.1M | $252.9M | +653,576 (+18.7%) | June 30, 2026 |
| 19 | Legal & General Group PLC | 0.85% | 3.8M | $231.7M | +437,632 (+13.0%) | June 30, 2026 |
| 20 | Amundi | 0.84% | 3.7M | $227.0M | +635,091 (+20.6%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 20.8M shares and 5 cut 9.7M.
RPRX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | American Funds New Perspective A | 4.34% | 19.3M | $1.18B | −308,214 (−1.6%) | September 30, 2026 |
| 2 | American Funds Capital Inc Bldr A | 1.67% | 7.4M | $452.8M | −1.2M (−13.5%) | September 30, 2026 |
| 3 | American Funds Growth Fd of Amer A | 1.52% | 6.7M | $411.3M | −828,982 (−10.9%) | September 30, 2026 |
| 4 | Morgan Stanley Inst Growth I | 1.10% | 4.9M | $299.4M | −299,268 (−5.7%) | June 30, 2026 |
| 5 | MS INVF US Advantage I | 1.08% | 4.8M | $292.9M | — | September 30, 2026 |
| 6 | MS INVF US Growth I | 0.80% | 3.6M | $218.0M | — | September 30, 2026 |
| 7 | Swedbank Robur Aktiefond Pension | 0.77% | 3.4M | $210.0M | +19,400 (+0.6%) | September 30, 2026 |
| 8 | T. Rowe Price Value | 0.75% | 3.4M | $204.7M | — | September 30, 2026 |
| 9 | VictoryShares Free Cash Flow ETF | 0.72% | 3.2M | $194.2M | +2,235 (+0.1%) | September 30, 2026 |
| 10 | Swedbank Robur Transfer 70 | 0.68% | 3.0M | $185.1M | −187,300 (−5.8%) | September 30, 2026 |
| 11 | T. Rowe Price Health Sciences | 0.59% | 2.6M | $159.8M | +143,900 (+5.8%) | September 30, 2026 |
| 12 | Latitude Global I GBP Acc | 0.56% | 2.5M | $151.4M | +66,443 (+2.7%) | September 30, 2026 |
| 13 | Capital Group NewPers LUX Z | 0.54% | 2.4M | $147.8M | −63,194 (−2.5%) | June 30, 2026 |
| 14 | Patient Opportunity C | 0.54% | 2.4M | $146.3M | −100,000 (−4.0%) | September 30, 2026 |
| 15 | Invesco Discovery Mid Cap Growth Y | 0.45% | 2.0M | $122.0M | +293,560 (+17.2%) | August 31, 2026 |
| 16 | BrighthouseI Morgan Stanley Discovery B | 0.43% | 1.9M | $115.9M | — | June 30, 2026 |
| 17 | Fidelity Extended Market Index | 0.43% | 1.9M | $115.7M | −24,272 (−1.3%) | August 31, 2026 |
| 18 | Transamerica Capital Growth A | 0.42% | 1.9M | $113.1M | — | September 30, 2026 |
| 19 | Strategic Advisers Fidelity US TtlStk | 0.39% | 1.7M | $106.2M | — | August 31, 2026 |
| 20 | American Funds IS® Growth 1 | 0.39% | 1.7M | $105.4M | +70,203 (+4.2%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
RPRX insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Terrance P Coyne | Sell | $48.33 | 34,791 | $1.7M |
| 2026-03-23 | Terrance P Coyne | Sell | $45.53 | 34,791 | $1.6M |
| 2026-03-02 | Terrance P Coyne | Sell | $46.78 | 34,791 | $1.6M |
| 2026-02-04 | Terrance P Coyne | Sell | $43.29 | 20,163 | $872,856 |
| 2026-02-03 | Terrance P Coyne | Sell | $42.84 | 114,954 | $4.9M |
| 2026-02-02 | Terrance P Coyne | Sell | $42.08 | 108,424 | $4.6M |
| 2026-01-30 | Marshall Urist | Sell | $41.09 | 20,000 | $821,800 |
| 2026-01-23 | Marshall Urist | Sell | $40.26 | 20,000 | $805,200 |
| 2026-01-20 | Terrance P Coyne | Sell | $39.35 | 69,582 | $2.7M |
| 2026-01-16 | Marshall Urist | Sell | $39.52 | 20,000 | $790,400 |
| 2026-01-09 | Marshall Urist | Sell | $40.78 | 20,000 | $815,600 |
| 2026-01-02 | Terrance P Coyne | Sell | $38.42 | 69,582 | $2.7M |
| 2025-12-26 | Marshall Urist | Sell | $39.32 | 20,000 | $786,400 |
| 2025-12-19 | Marshall Urist | Sell | $38.38 | 20,000 | $767,600 |
| 2025-12-18 | George W Lloyd | Sell | $38.50 | 30,654 | $1.2M |
| 2025-12-17 | George W Lloyd | Sell | $38.57 | 79,346 | $3.1M |
| 2025-12-16 | Marshall Urist | Sell | $38.32 | 20,000 | $766,400 |
| 2025-12-15 | Terrance P Coyne | Sell | $38.36 | 69,582 | $2.7M |
| 2025-12-05 | Marshall Urist | Sell | $39.15 | 18,242 | $714,174 |
| 2025-12-05 | Marshall Urist | Sell | $39.15 | 23,334 | $913,526 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
RPRX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns RPRX
Institutional investors own 87.7% of Royalty Pharma's shares and insiders 6.49%. The largest holder is Morgan Stanley - Brokerage Accounts with 9.64% of the shares (42.9M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 5 reduced their stake in the latest filings. Short interest is 2.93% of the float, or 3.89 days of average trading volume. The share count rose 125.0% since 2013.
Related: RPRX analyst forecast, RPRX key metrics, RPRX dividend history. See the RPRX stock overview for the latest quote and news.
RPRX ownership FAQ
Who owns the most Royalty Pharma stock?
The largest shareholders of Royalty Pharma are Morgan Stanley - Brokerage Accounts (9.64%), Capital Research & Mgmt Co - Division 3 (7.92%), BlackRock Inc (6.25%), FMR Inc (5.51%), State Street Corp (2.77%).
What percentage of Royalty Pharma is owned by institutions?
Institutions hold 87.7% of Royalty Pharma's shares outstanding; insiders hold 6.49%.
Which funds own Royalty Pharma?
The largest fund holders of Royalty Pharma are American Funds New Perspective A (4.34%), American Funds Capital Inc Bldr A (1.67%), American Funds Growth Fd of Amer A (1.52%), Morgan Stanley Inst Growth I (1.10%), MS INVF US Advantage I (1.08%).
What is Royalty Pharma's short interest?
12.9M shares of Royalty Pharma were sold short, 2.93% of the float; at the average daily volume it would take 3.89 days to cover.
Are insiders buying or selling Royalty Pharma?
Of the latest 20 reported insider transactions in Royalty Pharma (since December 5, 2025), 0 were purchases and 20 were sales.
How many shares of Royalty Pharma are outstanding?
Royalty Pharma has 445.3M shares outstanding, of which 417.6M are in the public float.